Trial Profile
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 25 Oct 2023 Planned End Date changed from 30 May 2023 to 30 May 2024.
- 22 Mar 2023 Planned End Date changed from 30 Dec 2022 to 30 May 2023.
- 17 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Dec 2022.